Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-046-9 | CAS number: 91-17-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
NTP studies with rats and mice with two years inhalation exposure have been conducted. No increased incidence of neoplastic effects was noted in male mice or in female rats at dose levels up to 400 ppm. Increased incidence of renal carcinoma or adenoma at 50 ppm or greater was observed in male rats. The identified mechanism (renal toxicity by accumulation of hyaline droplets, a2u-globulin accumulation) is considered to be species and sex specific with no relevance to human health risk. Some minor increases of neoplastic effects in liver and uterus of female mice could not unequivocally attributed to decahydronaphthalene with the data available.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Link to relevant study records
- Endpoint:
- carcinogenicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997-08-14 to 1999-08-19
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Comparable to Guideline study
- Principles of method if other than guideline:
- NTP Carcinogenicity Study
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Source: Taconic Laboratory Animals and Services, Germantown (NY, USA)
- Age: 7 weeks at study initiation
- Weight at study initiation: males mean 120 g, females mean 96 g
- Number of animals: 50 per concentration level and sex (400 ppm males: 20 animals)
- Housing: individually, Stainless steel wire-bottom (Lab Products, Inc., Seaford, DE)
- Food (ad libitum except during exposure): NTP-2000 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), irradiated
- Water (ad libitum): tap water
ENVIRONMENTAL CONDITIONS (CHAMBER)
- Temperature: 72° ± 3° F
- Relative humidity: 50% ± 15%
- Room fluorescent light: 12 hours/day
- Chamber air changes: 15/hour - Route of administration:
- inhalation
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: clean air
- Details on exposure:
- ADMINISTRATION / EXPOSURE
- Type of exposure: whole-body inhalation
- Vehicle: clean air
- Concentrations: established within 12 minutes, monitored every 24 minutes
males: 0, 25, 50; 100 ppm; additional 400 ppm group with only 20 animals At 72 +- 3 °F (22.2 °C) these ppm concentrations correspond
to: 0, 143, 285, 570; 2282 mg/m3
females: 0, 25, 100, 400 ppm (0, 143, 570, 2282 mg/m3) - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentrations in the exposure chambers were monitored every 24 minutes by an on-line gas chromatograph
- Duration of treatment / exposure:
- 105 weeks
- Frequency of treatment:
- 6 hours (+ 12 minutes concentration buildup)/day, 5 days/week
- Post exposure period:
- Post-exposure period: none
- Remarks:
- Doses / Concentrations:
25, 100, or 400 ppm; male rats also 50 ppm
Basis:
analytical conc. - No. of animals per sex per dose:
- 50 per concentration level and sex (400 ppm males: 20 animals)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- no data
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS AND FREQUENCY
- Clinical signs: observed twice daily
- Mortality: observed twice daily
- Clinical findings: every 4 weeks (weeks 5-89), every 2 weeks beginning week 92
- Body weight: initially every 4 weeks (weeks 5-89), every 2 weeks beginning week 92
- Hematology: none
- Clinical chemistry: none
- Urinalysis: none - Sacrifice and pathology:
- SACRIFICE
Carbon dioxide asphyxiation
PATHOLOGY
Necropsy was performed on all animals.
ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Macroscopic: "complete", no details reported
- Microscopic: all animals: gross lesions, adrenal gland, bone with marrow, brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, and mediastinal), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skin, spleen, stomach (forestomach and glandular), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.
OTHER EXAMINATIONS: Independent review of slides, individual animal data records, and pathology tables followed by clarification of any inconsistencies. - Statistics:
- STATISTICAL METHODS:
- probability of survival: procedure of Kaplan and Meier (1950)
- possible dose-related effects on survival: method of Cox (1972) and life table text of Tarone (1975)
- incidences of neoplasms or nonneoplastic lesions, also adjusted for survival: Poly-k test with k = 3
- organ and body weights: procedures of Dunnett (1955) and Williams (1971, 1972)
- hematology, clinical chemistry, urinalysis, renal toxicity, and spermatid and epididymal spermatozoal data: methods of Shirley (1977) and
Dunn (1964)
- selection of trend-sensitive vs. non-trend-sensitive statistical test: Jonckheere's test (1954)
- identification of outliers: test of Dixon and Massey (1951)
- average severity values: Mann-Whitney U test
- vaginal cytology data: arcsine transformation followed by multivariate analysis of variance - Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- reduced for 400 ppm males
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- male rats kidney effects
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- male rats kidney effects (chronic nephropathy, renal tubule hyperplasia, hyaline droplet accumulation, renal papilla mineralization, pelvic transitional epithelium hyperplasia)
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- males rats kidney (renal tubule adenoma, renal tubule adenoma or carcinoma), male rats adrenal medulla (benign or malignant pheochromocytoma)
- Details on results:
- Result (carcinogenicity): ambiguous
CLINICAL SIGNS: There were no exposure-related clinical findings.
BODY WEIGHT GAIN: Mean body weights of 400 ppm males were slightly less than those of the control group during the second year of the study
(initial +2 %, minimum -7 %, final -2 % from control).
PATHOLOGY: Statistically significant observations in females (sorted by increasing exposure concentrations):
- Interstitial fibrosis (16/50; 24/50;,23/49; 28/50**)
- Histiocytic infiltration (21/50; 26/50; 29/49; 29/50*)
- Aleolar proteinosis (11/50; 16/50; 15/49; 23/50**)
- Chronic inflammation of visceral pleura (15/50; 17/50; 23/49; 27/50*)
These changes are all components of a focal lesion that appears to be a common incidental finding in aged F344/N rats. They were not considered to be clinically significant
Nonneoplastic effects in kidneys of males (sorted by increasing exposure concentrations):
- Severity of chronic nephropathy (1.4; 2.3; 2.6; 2.3; 3.0)
- Renal tubule hyperplasia (0/50; 11/50**; 11/49**; 15/50**; 5/20**)
- Hyaline droplet accumulation (2/50; 9/50*; 7/49; 11/50**; 2/20)
-Renal papilla mineralization (1/50; 34/50**; 41/49**; 43/50**; 17/20**)
- Pelvic transitional epithelium hyperplasia (1/50; 8/50*; 8/49*; 10/50**; 5/20**)
Neoplastic effects in males (sorted by increasing exposure concentrations):
- Renal tubule adenoma (1/50; 2/50; 6/49; 9/50**; 5/20**).
- Renal tubule adenoma or carcinoma (1/50; 3/50; 7/49*; 12/50***; 6/20***)
- Adrenal medulla: benign or malignant pheochromocytoma (8/49; 9/49; 13/49; 16/49*; 8/20*)
SIGNIFICANCE: * p <= 0.05; ** p <= 0.01; *** p <= 0.001
OTHER: There was a significant association between nephropathy severity and adrenal pheochromocytoma incidence.
TIME TO TUMOURS: Renal tubule adenoma or carcinoma first observed after
0 ppm: 733 days = terminal necropsy;
25 ppm: 644 days
50 ppm: 680 days
100 ppm: 617 days
400 ppm: 708 days - Dose descriptor:
- NOAEC
- Effect level:
- > 400 ppm
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- NOAEC
- Effect level:
- 25 ppm
- Based on:
- act. ingr.
- Sex:
- male
- Basis for effect level:
- other: see 'Remark'
- Conclusions:
- Under the conditions of the study, there was clear evidence of carcinogenic activity of decahydronaphthalene in male F344/N rats based on
increased incidences of renal tubule neoplasms. The increased incidences of benign or malignant pheochromocytoma (combined) of the adrenal
medulla in male rats were also considered to be exposure related. There was no evidence of carcinogenic activity of decahydronaphthalene in
female F344/N rats.
Exposure of male rats to decahydronaphthalene resulted in nonneoplastic lesions of the kidney characteristic of a2u-globulin accumulation. - Executive summary:
Groups of 50 male and 50 female F344/N rats were exposed to 0, 25, 50 (male rats only), 100, or 400 ppm (female rats only) decalin vapor 6 hours per day, 5 days per week for 105 weeks. A group of 20 male rats was exposed to 400 ppm. Survival of exposed groups was similar to that of the chamber control groups. Mean body weights of 400 ppm males were slightly less than those of the chamber controls during the second year of the study. Incidences of renal tubule adenoma and adenoma or carcinoma (combined) and of benign or malignant pheochromocytoma (combined) of the adrenal medulla in 100 and 400 ppm males were significantly increased. There was a significant association between nephropathy severity and adrenal pheochromocytoma incidence. Nonneoplastic lesions related to decalin exposure occurred in the kidney of male rats.
- Endpoint:
- carcinogenicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997-08-28 to 1999-09-03
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Comparable to Guideline study
- Principles of method if other than guideline:
- Method: other: NTP Carcinogenicity Study
- GLP compliance:
- yes
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Source: Taconic Laboratory Animals and Services, Germantown (NY, USA)
- Age: 6 weeks at study initiation
- Weight at study initiation: males mean 24.1 g, females mean 19.7 g
- Number of animals: 50 per sex and exposure level
- Housing: individually, Stainless steel wire-bottom (Lab Products, Inc., Seaford, DE)
- Food (ad libitum except during exposure): NTP-2000 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), irradiated
- Water (ad libitum): tap water
ENVIRONMENTAL CONDITIONS (CHAMBER)
- Temperature: 72° ± 3° F
- Relative humidity: 50% ± 15%
- Room fluorescent light: 12 hours/day
- Chamber air changes: 15/hour - Route of administration:
- inhalation
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: clean air
- Details on exposure:
- ADMINISTRATION / EXPOSURE
- Type of exposure: whole-body inhalation
- Vehicle: clean air
- Concentrations: established within 12 minutes, monitored every 24 minutes At 72 +- 3 °F (22.2 °C) the ppm concentrations correspond
to: 143, 570, 2282 mg/m3 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentrations in the exposure chambers were monitored every 24 minutes by an on-line gas chromatograph
- Duration of treatment / exposure:
- 105 weeks
- Frequency of treatment:
- 6 hours (+ 12 minutes concentration buildup)/day, 5 days/week
- Post exposure period:
- none
- Remarks:
- Doses / Concentrations:
25, 100, or 400 ppm
Basis:
analytical conc. - No. of animals per sex per dose:
- 50
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Post-exposure period: none
- Positive control:
- no
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS AND FREQUENCY
- Clinical signs: observed twice daily
- Mortality: observed twice daily
- Clinical findings: every 4 weeks (weeks 4-89), every 2 weeks beginning week 92
- Body weight: initially, every 4 weeks (weeks 4-89), every 2 weeks beginning week 92
- Hematology: none
- Clinical chemistry: none
- Urinalysis: none - Sacrifice and pathology:
- SACRIFICE
Carbon dioxide asphyxiation
PATHOLOGY
Necropsy was performed on all animals.
ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Macroscopic: "complete", no details reported
- Microscopic: all animals: gross lesions, adrenal gland, bone with marrow, brain, clitoral gland, esophagus, gall bladder, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, and mediastinal), mammary gland (females only), nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skin, spleen, stomach (forestomach and glandular), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder and uterus.
OTHER EXAMINATIONS: independent review of slides, individual animal data records, and pathology tables followed by clarification of any inconsistencies - Statistics:
- STATISTICAL METHODS:
- probability of survival: procedure of Kaplan and Meier (1950)
- possible dose-related effects on survival: method of Cox (1972) and life table text of Tarone (1975)
- incidences of neoplasms or nonneoplastic lesions, also adjusted for survival: Poly-k test with k = 3
- organ and body weights: procedures of Dunnett (1955) and Williams (1971, 1972)
- hematology, clinical chemistry, urinalysis, renal toxicity, and spermatid and epididymal spermatozoal data: methods of Shirley (1977) and Dunn (1964)
- selection of trend-sensitive vs. non-trend-sensitive statistical test: Jonckheere's test (1954)
- identification of outliers: test of Dixon and Massey (1951)
- average severity values: Mann-Whitney U test
- vaginal cytology data: arcsine transformation followed by multivariate analysis of variance - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Male mice, liver: eosinophilic focus, centrilobular hypertrophy, necrosis, syncytial alteration, erythrophagocytosis
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Result (carcinogenicity): ambiguous
CLINICAL SIGNS: There were no clinical findings related to exposure.
BODY WEIGHT GAIN: Mean body weights of exposed groups were generally similar to those of the control groups throughout the study.
PATHOLOGY:
- Males: Statistically significant findings (all in the liver)
- eosinophilic focus (10/50; 9/50, 7/50; 19/50*)
- centrilobular hypertrophy (2/50; 0/50; 4/50; 36/50**)
- necrosis (0/50; 1/50; 3/50; 19/50**)
- syncytial alteration (26/50; 28/50; 36/50*; 44/50**)
- erythrophagocytosis (0/50; 0/50; 0/50; 9/50**)
- Males: not statistically significant
- hepatocellular adenoma or carcinoma: 28/50; 26/50; 22/50; 34/50 (within historical control range)
- interstitial cell adenoma in testis: 0/50; 0/50; 0/50; 3/50. 400 ppm
incidence at upper end of historical control range, not considered to be exposure related
- Females: Statistically significant or dose-related findings
- liver hepatocellular adenoma (7/49; 13/50; 8/50; 17/50*)
- liver hepatocellular carcinoma (4/49; 16/50**; 6/50; 5/50)
- one of these two (11/49; 27/50***; 14/50; 20/50*): equivocal evidence
- uterus stromal polyp (0/49; 0/50; 2/50; 3/50)
- uterus stromal polyp or stromal sarcoma (0/49; 0/50; 2/50; 4/50): 400 ppm
incidence exceeds historical control range, may have been exposure related.
SIGNIFICANCE: * p <= 0.05; ** p <= 0.01; *** p <= 0.001
TIME TO TUMORS: First incidence of (order of increasing exposure concentration)
- hepatocellular adenoma or carcinoma in males: 384 / 495 / 448 / 552 days
- hepatocellular adenoma or carcinoma in females: 703 / 488 / 594 / 636 days - Dose descriptor:
- NOAEC
- Effect level:
- > 400 ppm
- Based on:
- act. ingr.
- Sex:
- male/female
- Conclusions:
- There was no evidence of carcinogenic activity of decahydronaphthalene in male B6C3F1 mice. There was equivocal evidence of carcinogenic activity of decahydronaphthalene in female B6C3F1 mice based on marginally increased incidences of hepatocellular and uterine neoplasms.
Nonneoplastic lesions of the liver were observed in male mice exposed to decahydronaphthalene. - Executive summary:
Groups of 50 male and 50 female B6C3F1 mice were exposed to 0, 25, 100, or 400 ppm decalin vapor 6 hours per day, 5 days per week for 105 weeks. Survival of exposed mice was similar to that of the chamber controls. Mean body weights of exposed groups were generally similar to those of the chamber control groups throughout the study. Increased incidences of hepatocellular neoplasms occurred in 25 and 400 ppm female mice, and the incidences of centrilobular hypertrophy, necrosis, syncytial alteration, and erythrophagocytosis of the liver in 400 ppm males were significantly increased. The incidences of uterine stromal polyp and stromal polyp or stromal sarcoma (combined) occurred with positive trends in female mice.
Referenceopen allclose all
MORTALITY AND TIME TO DEATH: Survival of exposed groups was similar to that of the control groups:
Survivors/total | Mean survival of deaths | |||
Concentration | Males | Females | Males | Females |
0 ppm | 28/50 | 32/50 | 684 days | 700 days |
25 ppm | 23/50 | 35/50 | 675 days | 713 days |
50 ppm | 23/49 | - | 697 days | - |
100 ppm | 20/50 | 39/50 | 673 days | 703 days |
400 ppm | 14/20 | 28/50 | 711 days | 683 days |
MORTALITY AND TIME TO DEATH:
Survival of exposed mice was similar to that of the controls:
Survivors/total | Mean survival | |||
Concentration | Males | Females | Males | Females |
0 ppm | 40/50 | 37/49 | 701 days | 708 days |
25 ppm | 41/50 | 28/50 | 697 days | 687 days |
100 ppm | 36/50 | 35/50 | 702 days | 695 days |
400 ppm | 34/50 | 36/50 | 697 days | 702 days |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- other: rat amd mouse
- Quality of whole database:
- Klimisch 1 (reliable without restrictions)
Carcinogenicity: via dermal route
Link to relevant study records
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Method: other: Carcinogenicity test
- GLP compliance:
- no
- Species:
- mouse
- Strain:
- other: C3H/He
- Sex:
- not specified
- Route of administration:
- dermal
- Duration of treatment / exposure:
- 50 weeks
- Frequency of treatment:
- 3 times/week
- Remarks:
- Doses / Concentrations:
50 µL
Basis:
other: mixture (1:1) of decahydronaphthalene/dodecane - No. of animals per sex per dose:
- 50
- Control animals:
- no
- Details on study design:
- Post-exposure period: none
- Relevance of carcinogenic effects / potential:
- No carcinogenic effects noted upon dermal application.
- Dose descriptor:
- NOAEL
- Effect level:
- 50 other: µL/animal/day
- Based on:
- other: 1:1 mixture of decahydronaphthalene: dodecane
- Sex:
- male/female
- Basis for effect level:
- other: No skin tumours were noted
- Remarks on result:
- other: Effect type: carcinogenicity
- Conclusions:
- Decahydronaphthlene did not induce tumors in mice following dermal application for 50 weeks.
- Executive summary:
In a study on the carcinogenicty of benzo-a-pyrene in groups of 20 -30 mice upon dermal application decahydronaphthalene was used as solvent and applied at 50 µL three times a week for 50 weeks.
Groups of mice were treated topically with decahydronaphthalene containing different concentrations of benzo-a-pyrene. No tumours were noted up to 0.02% benzo-a-pyrene.
Reference
No tumours (benign or malignant) were found in any test substance preparation (up to 0.02% benzo[a]pyrene in decahydronaphthalene).
"Positive" control: application of 0.02 % benzo[a]pyrene in decahydronaphthalene caused a tumour incidence of 50 % (5 malignant, 1 benign); mortality: 8/20.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- Klimisch 2 (reliable with restrictions)
Justification for classification or non-classification
No increase of neoplasm in male mice and female rats was noted. Effects noted in male rats are considered species and sex specific and are not relevant for humans.
Some minor increases of neoplastic effects in liver and uterus of female mice could not unequivocally attributed to decahydronaphthalene with the data available.
Therefore, no classification regarding carcinogenicity is required according to CLP Regulation 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.